TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05658510
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Placebo Film
Study: NCT06747338
Drug: HB1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB1801
Study: NCT06757738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, dosage form - capsules, dosing regimen - QD
Study: NCT06746402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06476509
Drug: LV232 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT06476509
Drug: LV232 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT06476509
Drug: LV232 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT06638307
Drug: MEN2312
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN2312 administered as oral tablets.
Study: NCT06776952
Drug: XNW5004 ; Chidamide placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: XNW5004 + Chidamide placebo
Study: NCT06776952
Drug: XNW5004 placebo; Chidamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: XNW5004 placebo + Chidamide
Study: NCT06614192
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06755944
Drug: XY03-EA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days.
Study: NCT06769048
Drug: Placebo-matching BI 1584862
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching BI 1584862
Study: NCT06427798
Drug: [203Pb]VMT-alpha-NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[203Pb\]VMT-alpha-NET (6 mCi) will be given IV at 7 days prior.
Study: NCT06772233
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Select a targeted drug that has been effective in previous treatments, such as Imatinib, Sunitinib, Regorafenib, or Ripretinib. Continue the original dosage and regimen until disease progression or unacceptable toxicity occurs.
Study: NCT04550377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active medication
Study: NCT06772168
Drug: CMG190303(Dapagliflozin/Rosuvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg
Study: NCT06772168
Drug: Comparator 1: Dapagliflozin/Rosuvastatin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo
Study: NCT06772168
Drug: Rosuvastatin/Dapagliflozin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
Study: NCT05737706
Drug: MRTX1133
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRAS G12D Inhibitor
Study: NCT06744569
Drug: CU-10101
Normalized name: Cu 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo
Study: NCT06715514
Drug: GLP-1 Receptor Agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wegovy®
Study: NCT05470114
Drug: LEO 138559
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 138559 is an antibody given by subcutaneous injection.
Study: NCT05470114
Drug: Dupixent®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupixent® is an antibody given by subcutaneous injection.
Study: NCT06766578
Drug: Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first and third cycles are 5×3Gy radiotherapy D1 to 5, intravenous administration for tirelizumab 200 mg D6, intravenous administration for oxaliplatin 130 mg/m2 D6, and oral administration twice a day for S-1 40 mg/m2 D6 to 19. The second and fourth cycles are intravenous administration for tirelizumab 200 mg D1, intravenous administration for oxaliplatin 130 mg/m2 D1, and oral administration twice a day for S-1 40 mg/m2 D1 to 14. Every treatment cycle is spaced 1 week apart.
Study: NCT06766578
Drug: Adjuvant therapy(SOX chemotherapy)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
Study: NCT06764303
Drug: NTQ5082
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTQ5082 100mg qd
Study: NCT06755541
Drug: Fenofibrate in Combination With Ursodeoxycholic Acid
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Fenofibrate 200 mg Capsules
Study: NCT06764017
Drug: CHiR-DEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.
Study: NCT06780345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanically ventilated neonates will receive the usual protocol of sepsis and a placebo without vitamin C.
Study: NCT06773091
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.
Study: NCT06797427
Drug: DPH001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg
Study: NCT05720065
Drug: Isotonic saline 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized double-blind administration
Study: NCT06728176
Drug: MT1988
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Drug
Study: NCT06728176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05486182
Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of one dose of 18F FES for PET/CT imaging
Study: NCT05170399
Drug: AREXVY, ABRYSVO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory Syncytial Virus Vaccine
Study: NCT05540574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo given orally
Study: NCT06294990
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two years treatment with testosterone
Study: NCT06564311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06083207
Drug: IBI3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
Study: NCT06466798
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg methotrexate infusions will be given intraventricularly daily for 4 consecutive days per week every other week for 12 weeks.
Study: NCT06088004
Drug: ABO2011 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
Study: NCT05868369
Drug: Standard pain management regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).
Study: NCT06619600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo qd
Study: NCT04040452
Drug: Continuous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
Study: NCT05326035
Drug: WJ05129
Approvals — FDA: no, EMA: no, PMDA: no
Description: WJ05129:Twice daily (except for single dose), 12 hours apart, fixed time is recommended
Study: NCT05964140
Drug: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).
Study: NCT06029673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04594642
Drug: AZD0486 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
Study: NCT05357989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC (vegetarian source) capsule shells
Study: NCT03984565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
Study: NCT06667869
Drug: Sedative
Normalized name: Sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.
Study: NCT06073132
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Study: NCT05940493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06489431
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglycoside antibiotic irrigation
Study: NCT05850520
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham procedure will be given on visits when an active injection is not planned.
Study: NCT06013956
Drug: Carbidopa 25/Levodopa 100Mg Tab
Normalized name: CARBIDOPA 25/LEVODOPA 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-parkinsonian medication.
Study: NCT04994509
Drug: Placebo SC LEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via SC injections
Study: NCT04994509
Drug: PTM F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT04994509
Drug: PTM F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06315881
Drug: Cigarette
Normalized name: CIGARETTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoke usual brand cigarette
Study: NCT06498713
Drug: Acetaminophen 650 mg Oral Tablet
Normalized name: acetaminophen 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg pills
Study: NCT06498713
Drug: Acetaminophen 650mg Liquid
Normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg liquid
Study: NCT05667805
Drug: Platelet Concentrate
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal use (standard treatment)
Study: NCT05073003
Drug: altSonflex Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1_Adults_Placebo_GR1 and ST1_Adults_Placebo_GR2 groups in Stage 1 (Europe).
Study: NCT06343376
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06780085
Drug: Docetetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06780215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-3: 1 tablet/dose, once daily. Days 4-42: 1 tablet/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 1 tablet/dose, once daily.
Study: NCT06738966
Drug: BL0175
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL0175 is a nano-medicine for cancer therapy. Nano-medicine means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue.
Study: NCT06546670
Drug: ITU512
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITU512 is an investigational, oral, low molecular weight (LMW) compound.
Study: NCT06546670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
Study: NCT04517435
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
Study: NCT04517435
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
Study: NCT06780111
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 via IV infusion
Study: NCT06780787
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06780787
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06780787
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06774313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06774313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Injection
Study: NCT06774885
Drug: Folic Acid 1 Mg Oral Tablet
Normalized name: FOLIC ACID 1 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral folic acid tablet
Study: NCT06774885
Drug: Folic Acid 5 Mg Oral Tablet
Normalized name: folic acid 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral folic acid tablet
Study: NCT05970224
Drug: Ir-CPI
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive a single intravenous dose of Ir-CPI during 48 hours
Study: NCT06349473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as single SC injection.
Study: NCT05661682
Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralement without Manganese Sulfate
Study: NCT05071352
Drug: Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Approvals — FDA: no, EMA: no, PMDA: no
Description: In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
Study: NCT05340582
Drug: Acetaminophen Injection
Normalized name: acetaminophen Injection
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
Study: NCT05340582
Drug: Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
Study: NCT06677554
Drug: Addition of ultrasound with contrast injection (SonoVue®)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of contrast evaluation with SonoVue® injection (5 min including 1 min of acquisition) within the diagnostic strategy
Study: NCT05003063
Drug: Donepzil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test
Study: NCT05003063
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test
Study: NCT05849298
Drug: AAA617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
Study: NCT05849298
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed by the local investigator
Study: NCT05019027
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and until subsequently discontinued (or the lowest dose the subject can safely tolerate).~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol
Study: NCT05629689
Drug: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Study: NCT05629689
Drug: GEH200520 Injection / GEH200521 (18F) Injection - Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Study: NCT05252390
Drug: NUV-868
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUV-868 is an investigational drug for oral dosing.
Study: NCT05062980
Drug: Investigator's Treatment of Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
Study: NCT06430580
Drug: Hydrocortisone Oral
Normalized name: hydrocortisone Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg hydrocortisone, single oral dose
Study: NCT06128980
Drug: GDMT
Normalized name: Guideline-Directed Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
Study: NCT05059223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken twice daily
Study: NCT06240741
Drug: 68Ge/68Ga Generator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radionuclide generator
Study: NCT05353257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Q3W
Study: NCT04919226
Drug: CAPTEM (Capecitabine and Temozolomide)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Study: NCT04971785
Drug: PTM SEMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as SC injection
Study: NCT04971785
Drug: PTM CILO/FIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06730386
Drug: AK138D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.
Study: NCT05566262
Drug: Bodewell Calming Cream
Normalized name: Eucerin Calming Itch Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
Study: NCT06542874
Drug: NNC0487-0111 subcutanous
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0487-0111 administered subcutanously (under the skin)
Study: NCT06542874
Drug: Placebo (NNC0487-0111 subcutanous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0487-0111 placebo administered subcutanously (under the skin)
Study: NCT06542874
Drug: NNC0487-0111 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0487-0111 administered orally (in the mouth)
Study: NCT06542874
Drug: Placebo (NNC0487-0111 oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0487-0111 placebo administered orally (in the mouth)